TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01244763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule
Study: NCT03871881

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
Study: NCT01897415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
Study: NCT02426242

Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
Study: NCT01782183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal camera by Flir -HM series.
Description: The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
Study: NCT04618497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
Study: NCT01748448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: * prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arachides oleum raffinatum
Study: NCT03871881

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: A special designed neuropsychological test battery of validated tests to assess function of cognitive domains

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: A special designed neuropsychological test battery of validated tests to assess function of cognitive domains

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
Study: NCT03407391

Intervention type: OTHER
Intervention: None - observational
Description: No intervention - observational only

Intervention type: OTHER
Intervention: None - observational
Description: No intervention - observational only

Intervention type: OTHER
Intervention: None - observational
Description: No intervention - observational only
Study: NCT01825044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT 5 mg/kg/day
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NeuroSTAT 10 mg/kg/day
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Study: NCT01140516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: 2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simple Syrup
Description: 2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
Study: NCT00916799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Telehealth equipment (Viterian V-100)
Description: Patient will daily enter answers to questions generated from a home telehealth monitor
Study: NCT03907735

Intervention type: OTHER
Intervention: Myometrial tissue sample collection
Description: Myometrial tissue samples by core needle biopsy under ultrasound guidance

Intervention type: OTHER
Intervention: Myometrial tissue sample collection
Description: Myometrial tissue samples by core needle biopsy under ultrasound guidance

Intervention type: OTHER
Intervention: Myometrial tissue sample collection
Description: Myometrial tissue samples by core needle biopsy under ultrasound guidance

Intervention type: OTHER
Intervention: Myometrial tissue sample collection
Description: Myometrial tissue samples by core needle biopsy under ultrasound guidance
Study: NCT04510922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa 100 MG [Northera]
Description: droxidopa taken three times a day titrated up to a maximum of 600 mg.
Study: NCT01411293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Fat Milk
Description: Participants will ingest 2 cups of low-fat milk on 1 occasion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice Milk
Description: Participants will ingest 2 cups of rice milk on 1 occasion.
Study: NCT04399967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-based support
Description: Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD plus COVID-specific advice
Description: Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 related health warning leaflet
Description: The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-based support
Description: Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH Self-help smoking cessation booklet
Description: A general smoking cessation self-help booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH Self-help smoking cessation booklet
Description: A general smoking cessation self-help booklet
Study: NCT00175006

Intervention type: OTHER
Intervention: Measurement of Tophi to validate procedure
Description: Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
Study: NCT01302041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study: NCT04175197

Intervention type: DEVICE
Intervention: Drug Coated Balloon
Description: Legflow Drug Coated Balloon
Study: NCT04196842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring devices
Description: Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
Study: NCT01348178

Intervention type: PROCEDURE
Intervention: Follow-up
Description: Follow-up
Study: NCT03065673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate 5% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study: NCT01447173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
Study: NCT02225223

Intervention type: DEVICE
Group type: OTHER
Intervention: STAR™ Tumor Ablation System
Description: Targeted-radiofrequency ablation (t-RFA)

Intervention type: DEVICE
Group type: OTHER
Intervention: STAR™ Tumor Ablation System
Description: Targeted-radiofrequency ablation (t-RFA)

Intervention type: DEVICE
Group type: OTHER
Intervention: StabiliT® Vertebral Augmentation System
Description: Radiofrequency-targeted vertebral augmentation (RF-TVA)

Intervention type: DEVICE
Group type: OTHER
Intervention: StabiliT® Vertebral Augmentation System
Description: Radiofrequency-targeted vertebral augmentation (RF-TVA)
Study: NCT03272477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perjeta Injectable Product
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta Injectable Product
Description: Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
Study: NCT01476579

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Computer Tomography
Description: Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
Study: NCT01446029

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Telemonitoring Device with Clinical Care Modules
Description: Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
Study: NCT03064893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alloderm
Description: Reconstruction material

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermacell
Description: Reconstruction material
Study: NCT04446975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA
Description: At the time of writing the prescription an automatic notification will appear on the care provider's screen that identifies a suggested post-discharge opioid dose within the electronic prescription pad. If approved by the provider, opioid-only prescriptions will be written as suggested. Final dosing decisions and drug choices will remain at the discretion of the treating provider.
Study: NCT02594696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Psychiatry Consultation (PPC)
Description: * The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~* The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~* The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~* The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~* Recommendations are documented in the medical record and communicated directly to the oncology team
Study: NCT04218136

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: A minimum of 4 blood samples and a maximum of 6 blood samples will be collected. Venous return blood samples collected as part of routine monitoring of patients for bioclinical parameters. Samples will be collected before start of the infusion and end of the infusion
Study: NCT01244009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
Study: NCT02184897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenograstim 10 microgram/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim 10 microgram/kg/day
Study: NCT03215225

Intervention type: PROCEDURE
Intervention: Root canal orthograde treatment
Study: NCT02900911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early rehabilitation
Description: Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months.
Study: NCT03272477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
Study: NCT02900911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late rehabilitation
Description: Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
Study: NCT01971307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SGE-PsyScan
Study: NCT03272477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
Study: NCT02273011

Intervention type: PROCEDURE
Intervention: caesarean section
Description: elective caesarean section under regional anesthesia

Intervention type: PROCEDURE
Intervention: caesarean section
Description: elective caesarean section under regional anesthesia
Study: NCT01491529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~* Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~* Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AFQ056 will be supplied as oral tablets.
Study: NCT03308058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding computer education
Description: Breastfeeding computer education
Study: NCT02647918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 2 single doses
Study: NCT03086122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
Study: NCT03318744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo resembling aspirin tablet will be be given to participants in control arm.
Study: NCT04648306

Intervention type: DEVICE
Intervention: Prophylactic Impella support for a non-emergent PCI
Description: Impella percutaneous mechanical circulatory support is placed via the femoral or axillary artery prior to a non-emergent PCI in patients at high risk for periprocedural complications including hemodynamic collapse.
Study: NCT04412564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: TQ-B3101 is a ALK inhibitor.